Markets

Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts

(RTTNews) - Gilead Sciences, Inc. (GILD) has submitted a New Drug Application for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis, to the Japanese Ministry of Health, Labor and Welfare. The NDA is supported by data from the Phase 3 FINCH clinical trial program.

"This new drug application is an important milestone as we continue to expand Gilead's presence in Japan to now also include inflammation," said Luc Hermans, President and Representative Director, Gilead Sciences, K.K.

Filgotinib is an investigational agent and is not approved anywhere globally.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More